Published in Q J Med on July 01, 1993
Myfortic Versus Azathioprine in Systemic Lupus Erythematosus | NCT00504244
A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity (2008) 5.89
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (2009) 3.34
Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum (2009) 2.58
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum (2013) 2.06
Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis (2004) 1.91
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther (2006) 1.82
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum (2007) 1.74
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) (2013) 1.58
Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest (2004) 1.52
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) (2009) 1.48
Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis (2006) 1.47
B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis (2007) 1.42
Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol (2008) 1.42
Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. Rheumatol Int (2013) 1.41
Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum (2009) 1.36
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis (2014) 1.35
The search for lupus biomarkers. Best Pract Res Clin Rheumatol (2009) 1.26
Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr Res (2009) 1.24
Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther (2014) 1.22
Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol (2010) 1.21
Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol (2014) 1.18
Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther (2012) 1.17
How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev (2008) 1.15
Numerical scoring for the Classic BILAG index. Rheumatology (Oxford) (2009) 1.13
Underexpression of mitochondrial-DNA encoded ATP synthesis-related genes and DNA repair genes in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.13
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant (2015) 1.12
Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis (1996) 1.10
Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther (2012) 1.10
Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis (2005) 1.09
Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol (2005) 1.07
Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr Nephrol (2007) 1.03
Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol (2002) 1.02
A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann Rheum Dis (1994) 0.98
Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum (2010) 0.98
How to monitor SLE in routine clinical practice. Ann Rheum Dis (2005) 0.97
Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther (2013) 0.95
Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res Ther (2009) 0.93
Retracted Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic. Rheumatol Int (2009) 0.93
Spontaneous immunoglobulin-producing capacity of cultures from lupus patients and normal donors following depletion of cells expressing CD19 or CD38. Clin Exp Immunol (1998) 0.93
Lupus-specific kidney deposits of HSP90 are associated with altered IgG idiotypic interactions of anti-HSP90 autoantibodies. Clin Exp Immunol (2002) 0.92
The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus. Clin Exp Immunol (2001) 0.92
Changes in apoptotic gene expression in lymphocytes from rheumatoid arthritis and systemic lupus erythematosus patients compared with healthy lymphocytes. J Clin Immunol (2010) 0.92
Toward the development of criteria for global flares in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 0.92
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biol Blood Marrow Transplant (2015) 0.92
Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology? Clin Exp Immunol (2004) 0.91
Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther (2009) 0.90
Serological and genetic characterization of a human monoclonal immunoglobulin G anti-DNA idiotype. J Clin Invest (1994) 0.89
[Systemic lupus erythematosus--activity and outcome]. Z Rheumatol (2006) 0.87
B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford) (2012) 0.85
Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus (2012) 0.85
Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population. J Rheumatol (2008) 0.85
Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2011) 0.84
Diffusion-weighted MR imaging of kidneys in patients with systemic lupus erythematosus: initial experience. Rheumatol Int (2009) 0.83
Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. Lupus Sci Med (2015) 0.83
Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 0.83
Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South America, Spain and Portugal. Lupus (2009) 0.82
Data quality challenges in systemic lupus erythematosus trials: how can this be optimized? Curr Rheumatol Rep (2012) 0.82
A critical review of clinical trials in systemic lupus erythematosus. Lupus (2016) 0.81
CD8⁺ Treg cells associated with decreasing disease activity after intravenous methylprednisolone pulse therapy in lupus nephritis with heavy proteinuria. PLoS One (2014) 0.80
Belimumab in systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis (2012) 0.80
Markers of childhood lupus nephritis indicating disease activity. Pediatr Nephrol (2010) 0.80
Disease activity measures in paediatric rheumatic diseases. Int J Rheumatol (2013) 0.79
Agrin signalling contributes to cell activation and is overexpressed in T lymphocytes from lupus patients. J Immunol (2007) 0.79
Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. J Biol Chem (2015) 0.79
Renal tubular dysfunction in children with systemic lupus erythematosus. Pediatr Nephrol (2004) 0.79
Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation. Auto Immun Highlights (2014) 0.78
Urine metabolome profiling of immune-mediated inflammatory diseases. BMC Med (2016) 0.78
Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside. Rheum Dis Clin North Am (2010) 0.78
Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus. Ann Rheum Dis (1995) 0.78
Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol (2015) 0.77
Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. Arthritis Res Ther (2014) 0.77
Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. Clin Ther (2011) 0.77
Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis. Arthritis Res Ther (2016) 0.77
Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus Sci Med (2015) 0.77
The use of immunosuppressive and cytotoxic drugs in non-malignant disease. Arch Dis Child (2000) 0.77
Lipid anti-lipid antibody responses correlate with disease activity in systemic lupus erythematosus. PLoS One (2013) 0.77
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Arthritis Res Ther (2015) 0.77
Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 0.76
IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. Arthritis Res Ther (2015) 0.76
MAGE-B2 autoantibody: a new biomarker for pediatric systemic lupus erythematosus. J Rheumatol (2008) 0.76
[Systemic lupus erythematosus. Target criteria for treatment]. Z Rheumatol (2009) 0.76
Presentation of SLE in UK primary care using the Clinical Practice Research Datalink. Lupus Sci Med (2017) 0.75
Whole-body MRI for full assessment and characterization of diffuse inflammatory myopathy. Acta Radiol Open (2016) 0.75
Lupus autoantibodies to native DNA preferentially bind DNA presented on PolIV. Immunology (2005) 0.75
Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. Ann Rheum Dis (2007) 0.75
Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative. Eur J Rheumatol (2016) 0.75
A meta-analysis of public microarray data identifies gene regulatory pathways deregulated in peripheral blood mononuclear cells from individuals with Systemic Lupus Erythematosus compared to those without. BMC Med Genomics (2016) 0.75
The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. Clin Rheumatol (2015) 0.75
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 6.88
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM (1994) 5.23
Quantitation of thermography in arthritis using multi-isothermal analysis. I. The thermographic index. Ann Rheum Dis (1974) 3.82
Human parvovirus arthropathy. Lancet (1985) 3.76
Proteins containing the UBA domain are able to bind to multi-ubiquitin chains. Nat Cell Biol (2001) 3.62
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
A comparison of the reliability of self-reported drug use and sexual behaviors using computer-assisted versus face-to-face interviewing. AIDS Educ Prev (2000) 3.02
Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum (1999) 2.99
Idiotypic cross-reactions of monoclonal human lupus autoantibodies. J Exp Med (1983) 2.96
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore) (1981) 2.84
The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum (1995) 2.82
Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet (1987) 2.81
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol (1995) 2.69
Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis (1984) 2.67
Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. Br J Rheumatol (1992) 2.58
Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest (1997) 2.57
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis (2010) 2.52
Generic and condition-specific outcome measures for people with osteoarthritis of the knee. Rheumatology (Oxford) (1999) 2.51
Efficacy of tests used to monitor rheumatoid arthritis. Lancet (1989) 2.50
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
Joint hypermobility leading to osteoarthrosis and chondrocalcinosis. Ann Rheum Dis (1978) 2.44
The importance of iron in rheumatoid disease. Lancet (1981) 2.44
A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J (1998) 2.43
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) (2005) 2.37
Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrob Agents Chemother (1972) 2.35
Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum (1997) 2.31
Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum (2000) 2.28
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Resolution of the identity of certain antigen-antibody systems in systemic lupus erythematosus and Sjögren's syndrome: an interlaboratory collaboration. Arthritis Rheum (1979) 2.19
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
The role of continuous background infusions in patient-controlled epidural analgesia for labor and delivery. Anesth Analg (1994) 2.17
Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol (1993) 2.15
A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol (1999) 2.12
Cause of death in rheumatoid arthritis. Br J Rheumatol (1984) 2.12
Mixed connective tissue disease--goodbye to all that. Br J Rheumatol (1992) 2.11
Disablement following stroke. Disabil Rehabil (1999) 2.10
Musculoskeletal pain is associated with a long-term increased risk of cancer and cardiovascular-related mortality. Rheumatology (Oxford) (2009) 2.09
Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med (1988) 2.09
Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet (1984) 2.08
Production of lymphokine mRNA by CD45R+ and CD45R- helper T cells from human peripheral blood and by human CD4+ T cell clones. J Immunol (1989) 2.03
Changes in rheumatology out-patient workload over 12 years in the South West of England. Rheumatology (Oxford) (2003) 2.02
Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists. Rheumatology (Oxford) (2007) 1.97
An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum (2005) 1.96
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2001) 1.96
Measuring outcome in rheumatoid arthritis--which measures are suitable for routine clinical use? Br J Rheumatol (1995) 1.91
Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study. Q J Med (1976) 1.90
Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest (1997) 1.89
Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med (1984) 1.88
The cell cycle genes cdc22+ and suc22+ of the fission yeast Schizosaccharomyces pombe encode the large and small subunits of ribonucleotide reductase. Mol Gen Genet (1993) 1.88
Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J (1973) 1.88
Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis (1984) 1.86
Intra-articular steroids in osteoarthritis. Rheumatol Rehabil (1980) 1.85
Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis. Ann Rheum Dis (1989) 1.85
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) (2005) 1.83
Rheumatology training in the United Kingdom: the trainees' perspective. Rheumatology (Oxford) (2004) 1.80
Classical versus non-renal Wegener's granulomatosis. Q J Med (1994) 1.79
Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum (1999) 1.78
Regulatory subunit interactions of the 26S proteasome, a complex problem. Trends Biochem Sci (2000) 1.77
Hepatitis-B antibody in polymyalgia Rheumatica. Lancet (1975) 1.77
Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol (1984) 1.76
Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. BMJ (1992) 1.72
Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis Rheum (2001) 1.71
The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum (2001) 1.71
The long-term effects of treating rheumatoid arthritis. J R Coll Physicians Lond (1983) 1.70
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Useful laboratory measurements in the management of systemic lupus erythematosus. Q J Med (1982) 1.68
From BILAG to BLIPS--disease activity assessment in lupus past, present and future. Lupus (2000) 1.68
Hypothalamo-pituitary-adrenal function in patients on long-term adrenocorticotrophin therapy. Ann Rheum Dis (1968) 1.68
The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis. Eur J Immunol (1994) 1.67
In vitro responses to a 65-kilodalton mycobacterial protein by synovial T cells from inflammatory arthritis patients. J Immunol (1989) 1.67
Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol (1996) 1.67
Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases. Ann Rheum Dis (1984) 1.66
IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy. Clin Exp Immunol (1981) 1.66
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65